Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Evaluation of Myobrace for Crossbite Correction in Mixed Dentition (Myo vs Frankel)

sunnuntai 20. syyskuuta 2026 päivittänyt: tharwa Ali Mokred AL-awadi, Sana'a University

Evaluation of the Myobrace Appliance in Correcting Crossbite During the Mixed Dentition Stage: A Randomized, Controlled Clinical Trial

This randomized controlled clinical trial will evaluate the effectiveness of the Myobrace appliance in correcting anterior and posterior crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare the clinical effects of Myobrace with those of the Frankel III appliance. The study will assess changes in occlusion, skeletal and dentoalveolar relationships, and soft tissue characteristics before and after treatment. The study will also evaluate the effectiveness of the two treatment approaches in improving crossbite correction and related orthodontic outcomes.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Crossbite is a common malocclusion in children and may involve anterior or posterior teeth. Early management during the mixed dentition stage may help improve the occlusal relationship and reduce the potential for progression of the malocclusion.

This randomized controlled clinical trial is designed to evaluate the effectiveness of the Myobrace appliance for the correction of crossbite in children aged 6 to 10 years during the mixed dentition stage. The study will compare treatment with the Myobrace appliance with treatment using the Frankel III appliance.

Eligible children with anterior and/or posterior crossbite will be allocated to one of the treatment groups according to the study randomization protocol. Participants will receive the assigned appliance and will be followed throughout the treatment period according to the study protocol.

Treatment effectiveness will be evaluated by comparing clinical and orthodontic measurements obtained before and after treatment. The assessment will include correction of the crossbite and changes in skeletal, dentoalveolar, and soft tissue relationships. Cephalometric analysis will be used to assess relevant skeletal, dentoalveolar, and soft tissue changes.

The study will provide clinical information regarding the effectiveness of Myobrace treatment for crossbite correction during the mixed dentition stage and will allow comparison of its treatment effects with those of the Frankel III appliance.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

40

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Amanat Al Asimah
      • Sanaa, Amanat Al Asimah, Jemen
        • Faculty of Dentistry, Sana'a University

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

6 vuotta - 10 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Clinical diagnosis of anterior crossbite, posterior crossbite, or both.
  • Yemeni children aged 6 to 10 years.
  • Children in the mixed dentition stage.
  • No history of prior orthodontic treatment.

Exclusion Criteria:

  • Children with craniofacial anomalies, such as cleft lip and palate.
  • Children with severe jaw misalignment requiring complex therapy.
  • Children with complete permanent dentition.
  • Children currently undergoing orthodontic treatment
  • Children or parents/guardians unwilling to provide informed consent or participate in the study.
  • Children with predicted or observed poor compliance, including behavioral issues that may interfere with treatment or study procedures.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Myobrace Group

Participants assigned to this arm will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. Participants will be instructed to wear the appliance for approximately 1-2 hours during the day and overnight, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Participants will receive the Myobrace® Interceptive Class III appliance during the mixed dentition stage. The appliance will be used according to the study treatment protocol, with instructions for approximately 1-2 hours of daytime wear and overnight wear, together with daily myofunctional exercises and instructions regarding nasal breathing, tongue posture, swallowing, and lip competence. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first.

Active Comparator: Frankel III Group

Participants assigned to this arm will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the clinical treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Participants will receive the Frankel III (FR-III) functional regulator during the mixed dentition stage. The appliance will be used according to the study treatment protocol. Treatment will continue until crossbite correction is achieved or for a maximum of 18 months, whichever occurs first. Clinical and cephalometric assessments will be performed before and after treatment to evaluate changes in skeletal, dentoalveolar, and occlusal relationships.

Muut nimet:
  • FR-III

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Crossbite Correction Status
Aikaikkuna: Baseline, and up to 18 months

Change in occlusal crossbite status from baseline to treatment completion, assessed clinically by the presence or absence of anterior and/or posterior crossbite. Complete correction is defined as establishment of a normal anterior and/or posterior buccolingual occlusal relationship according to the type of crossbite present at baseline. The change will be assessed for each participant by comparing the post-treatment crossbite status with the participant's baseline status. The changes will then be compared between the Myobrace and Frankel III groups.

Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Overjet
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in overjet, measured in millimeters (mm) as the horizontal distance between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overjet value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Overbite
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in overbite, measured in millimeters (mm) as the vertical overlap between the maxillary and mandibular incisors. The change will be calculated for each participant by comparing the post-treatment overbite value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Anterior Crossbite Correction
Aikaikkuna: Baseline, and up to 18 months.

Correction of anterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment anterior crossbite status with the participant's baseline status. Correction is defined as establishment of a positive or normal horizontal overlap between the maxillary and mandibular anterior teeth that were in crossbite at baseline. The proportion of participants achieving anterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Posterior Crossbite Correction
Aikaikkuna: Baseline, and up to 18 months.

Correction of posterior crossbite at treatment completion, assessed for each participant by comparing the post-treatment posterior crossbite status with the participant's baseline status. Correction is defined as establishment of a normal transverse buccolingual relationship between the maxillary and mandibular posterior teeth that were in crossbite at baseline. The proportion of participants achieving posterior crossbite correction will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in ANB
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the ANB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ANB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNA
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the SNA angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SNB
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the SNB angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SNB value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Wits Appraisal
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in Wits appraisal, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Wits appraisal value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-MP
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the SN-MP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-MP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in SN-OP
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the SN-OP angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment SN-OP value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ar-Go-Me (Gonial Angle)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Ar-Go-Me (gonial) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ar-Go-Me value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Y-axis (Por-Gns)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Y-axis (Por-Gns) angle, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Y-axis value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMA
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the FMA (Frankfort-Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in IMPA
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the IMPA (Incisor to Mandibular Plane Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment IMPA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in FMIA
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the FMIA (Frankfort-Mandibular Incisor Angle), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment FMIA value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in S-Go Ratio
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the S-Go ratio, expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the posterior facial height (S-Go) relative to the anterior facial height (N-Me). The change will be calculated for each participant by comparing the post-treatment S-Go ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UI-SN
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the UI-SN angle (Upper Incisor to SN Plane), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UI-SN value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Interincisal Angle (U1/L1)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the interincisal angle (U1/L1), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment interincisal angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Angle
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the U1/NA angle (Upper Incisor to NA), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in U1/NA Linear Measurement
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the linear U1/NA measurement (Upper Incisor to NA), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment U1/NA linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in L1/NB Angle
Aikaikkuna: Baseline, and up to 18 months

Change from baseline in the L1/NB angle (Lower Incisor to NB), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in L1/NB Linear Measurement
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the linear L1/NB measurement (Lower Incisor to NB), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment L1/NB linear measurement with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Nasolabial Angle (Cotg-Sn-Ls)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the nasolabial angle (Cotg-Sn-Ls), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment nasolabial angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Z Angle
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Z angle (Merritt), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Z angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in N-Pog-H Line (H Angle)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the N-Pog-H angle (H angle, Holdaway), measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment N-Pog-H angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Ls-NsPog (U lip /E line)
Aikaikkuna: Baseline, and up to 18 months

Change from baseline in the Ls-NsPog (upper lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Ls-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months
Change in Li-NsPog (Lower Lip / E-Line)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Li-NsPog (lower lip to E-line) measurement, measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Li-NsPog value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Sn-Stm : Stm-Me Ratio
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Sn-Stm : Stm-Me ratio (Legan and Burstone), expressed as a percentage (%), representing the ratio of the upper lip height (Sn-Stm) to the lower lip and chin height (Stm-Me) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in Gl-Sn-Pog (Facial Contour Angle)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the Gl-Sn-Pog facial contour angle (Glabella-Subnasale-Pogonion), representing the soft tissue angle of facial convexity, measured in degrees (°) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment Gl-Sn-Pog angle value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH (Upper Facial Height)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the upper facial height (UFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment UFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in LFH (Lower Facial Height)
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the lower facial height (LFH), measured in millimeters (mm) on standardized lateral cephalometric radiographs. The change will be calculated for each participant by comparing the post-treatment LFH value with the participant's baseline value. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.
Change in UFH: LFH ratio
Aikaikkuna: Baseline, and up to 18 months.

Change from baseline in the UFH: LFH ratio (Upper Facial Height to Lower Facial Height), expressed as a percentage (%) on standardized lateral cephalometric radiographs. The ratio represents the upper facial height (UFH) relative to the lower facial height (LFH). The change will be calculated for each participant by comparing the post-treatment UFH:LFH ratio with the participant's baseline ratio. The changes will then be compared between the Myobrace and Frankel III groups. Baseline and at treatment completion, defined as when anterior crossbite correction is achieved or at 18 months, whichever occurs first.

Baseline, and up to 18 months.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Dr.Tharwa Alawadi, BDS, MSc, Sana'a University, Faculty of Dentistry
  • Opintojen puheenjohtaja: Khaled AL-Haddad, Professor, Sana'a University, Faculty of Dentistry

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 23. huhtikuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Keskiviikko 1. syyskuuta 2027

Opintojen valmistuminen (Arvioitu)

Keskiviikko 1. syyskuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 14. syyskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Sunnuntai 20. syyskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 24. syyskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 24. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 20. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

Individual participant data will not be shared with other researchers. The study data will be used for the purposes of the current research and reported in aggregate form to protect participant confidentiality and privacy.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa